Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers

Learn More

Investor Relations Contact Information

T: 215-825-9306

IR@adaptimmune.com

For other contact information, please visit the Contact page.